The latest price target for Eledon Pharma (NASDAQ:ELDN) was reported by HC Wainwright & Co. on November 20, 2024. The analyst firm set a price target for $16.00 expecting ELDN to rise to within 12 months (a possible 268.66% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Eledon Pharma (NASDAQ:ELDN) was provided by HC Wainwright & Co., and Eledon Pharma reiterated their buy rating.

There is no last upgrade for Eledon Pharma

There is no last downgrade for Eledon Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eledon Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eledon Pharma was filed on November 20, 2024 so you should expect the next rating to be made available sometime around November 20, 2025.

While ratings are subjective and will change, the latest Eledon Pharma (ELDN) rating was a reiterated with a price target of $16.00 to $16.00. The current price Eledon Pharma (ELDN) is trading at is $4.34, which is out of the analyst’s predicted range.